Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated liposomal doxorubicin vs capecitabine in first-line metastatic breast cancer
2005-003164-35Phase 3Completed
- Sponsor
- Essex Bio-Technology Limited
- Start
- Sep 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Pegylated liposomal doxorubicin with Capecitabine (2 arms). Primary endpoint: Time to progression. Started Sep 2005; status: completed.
02
Drugs
doxorubicincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003164-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003164-35.